CancerDrs

Lung Cancer clinical trials in South Carolina

22 actively recruiting lung cancer trials at 20 sites across South Carolina.

Data from ClinicalTrials.gov · last refreshed

Phase 2, Phase 3 Recruiting Network

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protoco…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT03851445
Sites in South Carolina:
  • AnMed Health Cancer Center — Anderson, South Carolina
  • Saint Joseph's/Candler - Bluffton Campus — Bluffton, South Carolina
  • Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina
  • Ralph H Johnson VA Medical Center — Charleston, South Carolina
  • Medical University of South Carolina — Charleston, South Carolina
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Network

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

This phase II/III Expanded Lung-MAP treatment trial compares the effect of adding cemiplimab to docetaxel and ramucirumab versus docetaxel and ramucirumab alone in treating patients with non-small cell lung cancer that is stage IV or that …

Sponsor: SWOG Cancer Research Network
NCT ID: NCT06616584
Sites in South Carolina:
  • AnMed Health Cancer Center — Anderson, South Carolina
  • Saint Joseph's/Candler - Bluffton Campus — Bluffton, South Carolina
  • Medical University of South Carolina — Charleston, South Carolina
  • Gibbs Cancer Center-Gaffney — Gaffney, South Carolina
  • Gibbs Cancer Center-Pelham — Greer, South Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06498635
Sites in South Carolina:
  • Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina
  • Prisma Health Cancer Institute - Easley — Easley, South Carolina
  • Gibbs Cancer Center-Gaffney — Gaffney, South Carolina
  • Tidelands Georgetown Memorial Hospital — Georgetown, South Carolina
  • Prisma Health Cancer Institute - Butternut — Greenville, South Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…

Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in South Carolina:
  • Saint Francis Hospital — Greenville, South Carolina
  • Saint Francis Cancer Center — Greenville, South Carolina
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates fo…

Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT04613596
Sites in South Carolina:
  • Local Institution - Unk038 — Charleston, South Carolina
  • Local Institution - 007-5475 — Spartanburg, South Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if ol…

Sponsor: Eli Lilly and Company
NCT ID: NCT06890598
Sites in South Carolina:
  • Medical University of South Carolina — Charleston, South Carolina
  • Lexington Medical Center — West Columbia, South Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

Multicenter, randomized (2:1), open-label phase 3 study in HLA-A2 positive patients with squamous and non-squamous metastatic NSCLC with ICI secondary resistance. Patients will be randomized into 2 arms (randomization 2:1): experimental Ar…

Sponsor: OSE Immunotherapeutics
NCT ID: NCT06472245
Sites in South Carolina:
  • Bon Secours Hematology and Oncology — Greenville, South Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untr…

Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT06875310
Sites in South Carolina:
  • Local Institution - 0681 — Greenville, South Carolina
  • Local Institution - 0658 — Greenville, South Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC

This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) and domvanalimab (AB154) compared with durvalumab plus placebo in adults with lo…

Sponsor: AstraZeneca
NCT ID: NCT05211895
Sites in South Carolina:
  • Research Site — Charleston, South Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In

This is a randomized, two-cohort, open-label, phase 3, clinical trial to compare the efficacy and safety of N-803 plus tislelizumab and docetaxel (cohort A) or prior failed Health Authority-approved antiprogrammed death-1 (PD-1) or anti-pr…

Sponsor: ImmunityBio, Inc.
NCT ID: NCT06745908
Sites in South Carolina:
  • Medical University of South Carolina — Charleston, South Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tis…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT05642572
Sites in South Carolina:
  • AnMed Health Cancer Center — Anderson, South Carolina
  • Saint Joseph's/Candler - Bluffton Campus — Bluffton, South Carolina
  • Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina
  • Ralph H Johnson VA Medical Center — Charleston, South Carolina
  • Medical University of South Carolina — Charleston, South Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

The primary purpose of the study is to assess how well amivantamab in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth factor receptor mutated (EGFRm) non-smal…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06667076
Sites in South Carolina:
  • Medical University of South Carolina — Charleston, South Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC

This is an exploratory, signal finding, randomized, placebo-controlled, blinded, multi-center Phase 2b trial of the anti GDF-15 antibody Visugromab (CTL-002) versus Placebo, combined with Immunochemotherapy (ICT: Pembrolizumab, Pemetrexed,…

Sponsor: CatalYm GmbH
NCT ID: NCT07098988
Sites in South Carolina:
  • Medical University of South Carolina — Charleston, South Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Phase 2 Study of Fingolimod in Lung Cancers

This is a single-institution, open-labeled study using fingolimod (FTY720/Gilenya) in patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) who have progressed on chemo-immunotherapy. The study design will be a…

Sponsor: Medical University of South Carolina
NCT ID: NCT06424067
Sites in South Carolina:
  • Hollings Cancer Center at Medical University of South Carolina — Charleston, South Carolina
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizum…

Sponsor: Tizona Therapeutics, Inc
NCT ID: NCT04485013
Sites in South Carolina:
  • Medical University of South Carolina — Charleston, South Carolina
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of ZL-1310 in Subjects With Small Cell Lung Cancer

An open-label, multicenter study of ZL-1310 as a single agent and in combination with Atezolizumab (with and without Carboplatin) to evaluate the safety, efficacy, and pharmacokinetics in subjects with small cell lung cancer

Sponsor: Zai Lab (Shanghai) Co., Ltd.
NCT ID: NCT06179069
Sites in South Carolina:
  • Zai Lab Site 2012 — Charleston, South Carolina
View on ClinicalTrials.gov →
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in South Carolina:
  • AnMed Health Cancer Center — Anderson, South Carolina
  • Prisma Health Richland Hospital — Columbia, South Carolina
  • McLeod Regional Medical Center — Florence, South Carolina
  • Gibbs Cancer Center-Gaffney — Gaffney, South Carolina
  • Tidelands Georgetown Memorial Hospital — Georgetown, South Carolina
View on ClinicalTrials.gov →
Recruiting Academic/Other

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …

Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in South Carolina:
  • AnMed Health Cancer Center — Anderson, South Carolina
  • Beaufort Memorial Hospital — Beaufort, South Carolina
  • Saint Joseph's/Candler - Bluffton Campus — Bluffton, South Carolina
  • Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina
  • Medical University of South Carolina — Charleston, South Carolina
View on ClinicalTrials.gov →
Recruiting Academic/Other

LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia

This study evaluates cancer-related weight and muscle mass loss, symptoms, and physical function (cachexia) in patients undergoing treatment for colorectal, lung, or pancreatic cancer that cannot be removed by surgery (unresectable) or is …

Sponsor: University of Rochester
NCT ID: NCT06073431
Sites in South Carolina:
  • AnMed Health Cancer Center — Anderson, South Carolina
  • Saint Joseph's/Candler - Bluffton Campus — Bluffton, South Carolina
  • Gibbs Cancer Center-Gaffney — Gaffney, South Carolina
  • Prisma Health Cancer Institute - Butternut — Greenville, South Carolina
  • Prisma Health Cancer Institute - Faris — Greenville, South Carolina
View on ClinicalTrials.gov →
Recruiting Network

Testing Tumor Tissue and Blood to Help Select Personalized Treatments for Patients With Suspected Lung Cancers

This collaborative screening protocol, developed by the Lung Cancer Mutation Consortium (LCMC) and supported by the Thoracic Surgery Oncology Group (TSOG), is designed to determine the feasibility of comprehensive molecular profiling to de…

Sponsor: Lung Cancer Mutation Consortium
NCT ID: NCT04712877
Sites in South Carolina:
  • Medical University of South Carolina — Charleston, South Carolina
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-07-27